In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now.
The head biotech analyst at Goldman Sachs, Salveen Richter, made an appearance on CNBC’s “Squawk Box” on July 25 to discuss a variety of topics, including the status of the biotech industry and what to anticipate from the earnings season.
She said that the biotech and healthcare industries have experienced several years of negative earnings revision cycles, and she wants to see these businesses now hitting the figures.
They have begun to show some steadiness, Richter continued, and Q2 is usually a stronger quarter. As a result, some biotech businesses in the sector could produce impressive financial outcomes.
According to the expert, launches and pipelines beyond statistics are two more elements to take into account in the sector.
She mentioned that she will continue to keep an eye on the several medicine launches that have occurred this year. Speaking of pipelines that go beyond statistics, Richter said that pain and Alzheimer’s disease have begun to receive attention this season.
With this in mind, let’s now take a look at the top AI-Powered biotech stocks to buy now.
Our Methodology
For our methodology, we initially identified AI-powered companies through manual research and shortlisted 20 leading firms. From this list, we selected the 10 companies with the highest number of hedge fund holders as of Q2 2025, according to Insider Monkey’s database, and then ranked them in ascending order.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
Here is our list of the top 10 AI-powered biotech stocks to buy now.
10. Absci Corporation (NASDAQ:ABSI)
Number Of Hedge Fund Holders: 12
Absci Corporation (NASDAQ:ABSI), founded in 2018 and headquartered in Seattle, is pioneering the integration of deep learning with high-throughput lab automation to design and optimize biologics at scale. Its Integrated Drug Creation (IDC) platform combines proprietary algorithms with protein engineering, enabling rapid development of antibody and enzyme candidates for both pharma partners and its own pipeline. The stock is among the best biotech stocks.
Absci Corporation (NASDAQ:ABSI) recently expanded its partnership with Almirall, a leading dermatology-focused pharmaceutical firm, by launching a second program targeting chronic skin diseases. This builds on the successful delivery of a functional AI-designed antibody, further validating the firm’s technology. To strengthen its dermatology pipeline, Absci also appointed experts Dr. Rodney Sinclair and Dr. David Goldberg to advise on ABS-201, an AI-designed therapy for hair loss disorders such as androgenetic alopecia, which is expected to enter clinical evaluation in early 2026.
On the technology front, the business announced collaborations with Oracle Cloud Infrastructure and AMD to enhance its AI-driven drug discovery capabilities. The AMD partnership includes a strategic investment, giving the company access to advanced chip technology and cloud resources to scale model training and data processing.
Financially, Absci Corporation (NASDAQ:ABSI) boosted its balance sheet with $64 million in equity financing during July and August 2025, extending its operational runway through mid-2028. The funding will support the advancement of key pipeline programs, including ABS-101 and ABS-201, while accelerating partnered projects and strengthening the corporation’s AI infrastructure for next-generation drug discovery.
9. AbCellera Biologics Inc. (NASDAQ:ABCL)
Number Of Hedge Fund Holders: 17
AbCellera Biologics Inc. (NASDAQ:ABCL) is entering a new phase in 2025, shifting from discovery to clinical execution with multiple first-in-human trials now underway. In August, the company began Phase 1 studies for two AI-designed antibodies: ABCL575, targeting moderate-to-severe atopic dermatitis, and ABCL635, a first-in-class treatment for menopausal hot flashes. Both candidates leverage novel mechanisms, with ABCL575 showing strong safety and extended dosing potential, while ABCL635 offers a non-hormonal alternative for symptoms that remain underserved by current therapies.
Strengthening its leadership team, AbCellera Biologics Inc. (NASDAQ:ABCL) appointed Dr. Sarah Noonberg as Chief Medical Officer in September. Her expertise in clinical development is expected to accelerate regulatory progress and support the company’s expansion into new therapeutic areas, particularly immunological diseases.
The corporation’s momentum is reflected in its growing pipeline, which now includes 16 molecules in clinical development, alongside 97 initiated partner programs. This underscores robust demand for the business’s AI-powered antibody discovery platform, which combines advanced epitope mapping, microfluidics, and data-driven optimization to shorten the path from target identification to clinical trials.
Looking ahead, AbCellera Biologics Inc. (NASDAQ:ABCL) plans to launch additional clinical trials by the end of 2025, expand its integrated manufacturing capabilities, and continue scaling its AI platform.
